Possibilities of using some autoantibodies in the diagnosis of preeclampsia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the current Russian and foreign literature on a change in the level of various autoantibodies (autoAb) in the development of preeclampsia and on the possibility of its diagnostic use. Material and methods. The investigations included data from the Russian and foreign publications appearing during the past 15 years. Results. The results of clinical and immunological analyses suggest that one of the direct pathogenetic factors in the development of preeclampsia may be an abnormal decrease in the production of many autoAbs. Thus, the study of autoAbs is an additional reliable method to diagnose preeclampsia. Conclusion. Further immunological investigations are needed to understand the significance of autoAbs in the pathogenesis of preeclampsia.

Full Text

Restricted Access

About the authors

Angelina Ahmetovna Malsagova

A.I. Evdokimov Moscow State University of Medicine and Dentistry

obstetrician-gynecologist, postgraduate student, Department of Obstetrics and Gynecology, Faculty of Dentistry

Svetlana Grigorievna Tsakhilova

A.I. Evdokimov Moscow State University of Medicine and Dentistry; branch of City Clinical Hospital #68

MD, Professor, obstetrician-gynecologist

Jamilya Hazhbarovna Sarakhova

A.I. Evdokimov Moscow State University of Medicine and Dentistry

PhD, associate Professor of obstetrics and gynecology, Department of Obstetrics and Gynecology, Faculty of Dentistry

Antonina Vitalievna Khmelnitskaya

A.I. Evdokimov Moscow State University of Medicine and Dentistry; branch of City Clinical Hospital #68

obstetrician-gynecologist

Aida Mayrbekovna Begizova

A.I. Evdokimov Moscow State University of Medicine and Dentistry

PhD student, Department of Obstetrics and Gynecology, Faculty of Dentistry

Alexander B. Poletaev

A.I. Evdokimov Moscow State University of Medicine and Dentistry; MRC “Immunculus”; Principal researcher at P.K. Anokhin Research Institute of Normal Physiology

MD, Professor, immunologist

References

  1. Министерство здравоохранения и социального развития Российской Федерации «О материнской смертности в Российской Федерации в 2009 году». Методическое письмо от 21.02.2011 N 15-4/10/2-1694. [Ministry of Health and Social Development of the Russian Federation „On Maternal Mortality in the Russian Federation in 2009”. Methodical letter of 21.02.2011 N 15-4 / 10 / 2-1694. (in Russian)]
  2. Запорожец Э.Е., Шувалова М.П., Цымлякова Л.М., Фролова О.Г., Огрызко Е.В., Суханова Л.П. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. Статистическая форма №32 за 2012 год. М.: Российское общество акушеров-гинекологов, ФГБУ «НЦАГИП им. В.И. Кулакова» Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России; 2013: 48-50, 59-61. [Zaporozhets E.E., Shuvalova M.P., Tsyimlyakova L.M., Frolova O.G., Ogryizko E.V., Suhanova L.P. The main indicators of the activities of the mother and child health service in the Russian Federation. Statistical form number 32 for 2012. M: Russian Society of Obstetricians and Gynecologists, Research center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Central Research Institute of Health Care Informatization Organization, Ministry of Health of Russia; 2013: 48-50, 59-61. (in Russian)]
  3. Состояние здоровья беременных, рожениц, родильниц и новорожденных. Обновление от 14.12.2015. Данные Федеральной службы государственной статистики. [Электронный ресурс]. Available at: http://www.gks.ru/ free_doc/new_site/population/zdrav/zdr3-2.xls [The state of health of pregnant women, parturient women, puerperas and newborns. Update as of December 14, 2015. Data of the Federal State Statistics Service. [Electronic resource]. Available at: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr3-2. xls (in Russian)]
  4. Hutcheon J.A., Lisonkova S., Joseph K.S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(4): 391-403.
  5. Managing complications in pregnancy and childbirth: a guide for midwives and doctors. World Health Organization; 2000, reprint 2007. 390p.
  6. Keyes L.E., Armaza J.F., Niermeyer S., Vargas E., Young D.A., Moore L.G. Intrauterine growth restriction, preeclampsia, and intrauterine mortality at high altitude in Bolivia. Pediatr. Res. 2003; 54(1): 20-5.
  7. Weiler J., Tong S., Palmer K.R. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One. 2011; 6(10): e26937.
  8. Kenny L., English F., McCarthy F. Risk factors and effective management of preeclampsia. Integr. Blood Press. Control. 2015; 8: 7.
  9. American College of Obstetricians and Gynecologists. Hypertension in Pregnancy, practice guideline. American College of Obstetricians and Gynecologists; 2013.
  10. NICE clinical guideline 107. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. National Institute for Health and Clinical Excellence; 2010. 47p.
  11. Tranquilli A.L., Dekker G., Magee L., Roberts J., Sibai B.M., Steyn W. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4(2): 97-104.
  12. Bombrys A.E., Barton J.R., Nowacki E.A., Habli M., Pinder L., How H. et al. Expectant management of severe preeclampsia at less than 27 weeks’ gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am. J. Obstet. Gynecol. 2008; 199(3): 247. e1-6.
  13. Matsuo K., Kooshesh S., Dinc M., Sun C.-C.J., Kimura T., Baschat A.A. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am. J. Perinatol. 2007; 24(4): 257-66.
  14. Norwitz E.R., Repke J.T. Preeclampsia prevention and management. J. Soc. Gynecol. Investig. 2000; 7(1): 21-36.
  15. McMaster M.T., Zhou Y., Fisher S.J. Abnormal placentation and the syndrome of preeclampsia. Semin. Nephrol. 2004; 24(6): 540-7.
  16. Silasi M., Cohen B., Karumanchi S.A., Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet. Gynecol. Clin. North Am. 2010; 37(2): 239-53.
  17. Caniggia I., Mostachfi H., Winter J., Gassmann M., Lye S.J., Kuliszewski M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest. 2000; 105(5): 577-87.
  18. Goldman-Wohl D., Yagel S. NK cells and pre-eclampsia. Reprod. Biomed. Online. 2008; 16(2): 227-31.
  19. Сухих Г.Т., Ванько Л.В. Иммунные факторы в этиологии и патогенезе осложненной беременности. Акушерство и гинекология. 2012; 1: 128-36. [Sukhikh G.T., Vanko L.V. Immune factors in the etiology and pathogenesis of pregnancy complications. Akusherstvo i ginekologiya/Obstetrics and gynecology. 2012; (1): 128-36. (in Russian)]
  20. Burke S.D., Barrette V.F., Gravel J., Carter A.L.I., Hatta K., Zhang J. et al. Uterine NK cells, spiral artery modification and the regulation of blood pressure during mouse pregnancy. Am. J. Reprod. Immunol. 2010; 63(6): 472-81.
  21. Bouteiller P. Le., Pizzato N., Barakonyi A., Solier C. HLA-G, pre-eclampsia, immunity and vascular events. J. Reprod. Immunol. 2003; 59(2): 219-34.
  22. O’Brien M., Dausset J., Carosella E.D., Moreau P. Analysis of the role of HLA-G in preeclampsia. Hum. Immunol. 2000; 61(11): 1126-31.
  23. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004; 95(9): 884-91.
  24. Maynard S.E., Min J.-Y., Merchan J., Lim K.-H., Li J., Mondai S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649-58.
  25. Chaiworapongsa T., Romero R., Espinoza J., Bujold E.M., Kim Y., Goncalves L.F. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 2004; 190(6): 1541-7; discussion 1547-50.
  26. Levine R.J., Maynard S.E., Qian C., Lim K.-H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350(7): 672-83.
  27. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am. J. Obstet. Gynecol. 2006; 195(1): 255-9.
  28. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202(2): 161. e1-161. e11.
  29. Poletaev A.B., Churilov L.P., Stroev Yu I., Agapov M.M. Immunophysiology versus immunopathology: Natural autoimmunity in human health and disease. Pathophysiology. 2012; 19(3): 221-31.
  30. Poletaev A.B. The main principles of adaptive immune system function: self-recognition, self-interaction, and self-maintenance. In: Poletaev A.B., ed. Physiologic autoimmunity and preventive medicine. Sharjah, Oak Park, Bussum: Bentham Science Publishers; 2013: 3-20.
  31. Poletaev A.B. Autoantibodies: serum content or profiles? In: Poletaev A.B., ed. Physiologic autoimmunity and preventive medicine. Sharjah, Oak Park, Bussum: Bentham Science Publishers; 2013: 199-207.
  32. Полетаев А.Б. О «трудных вопросах» аутоиммунитета. Или как концепция иммункулуса может стать основой профилактической медицины. Медицина XXI век. 2008; 11(2): 84-91. [Poletaev A.B. About “difficult issues” of autoimmunity. Or how the concept of immunoculus can become the basis of preventive medicine. Meditsina XXI vek. 2008; 11(2): 84-91. (in Russian)]
  33. Wattts R.A. Autoantibodies in autoimmune diseases. Medicine. 2002; 30(10): 2-6.
  34. Замалеева Р.С., Мальцева Н.А., Черепанова Н.А., Букатина С.В., Нюхнин М.А. Клиническое значение определения уровня регуляторных аутоантител для оценки риска развития гестоза. Практическая медицина. 2009; 2: 68-71. [Zamaleeva R.S., Maltseva N.A., Cherepanova N.A., Bukatina S.V., Nyuhnin M.A. Clinical significance of determining the level of regulatory autoantibodies for assessing the risk of gestosis. Prakticheskaya meditsina. 2009; 2: 68-71. (in Russian)]
  35. Kalden J.R., Herrmann M., eds. Apoptosis and autoimmunity: from mechanisms to treatments. Wiley-Blackwell; 2006. 392p.
  36. Слободина А.В. Возможности прогнозирования тяжелой преэклампсии: дисс.. канд. мед. наук. Омск; 2015. 136с. [Slobodina A.V. Possibilities of predicting severe preeclampsia. Diss.Omsk; 2015. 136p. (in Russian)]
  37. Замалеева Р.С., Черепанова Н.А., Букатина С.В., Нюхнин М.А. Определение уровня регуляторных аутоантител для оценки риска развития гестоза. Медицинский альманах. 2008; 5: 56-60. [Zamaleeva R.S., Cherepanova N.A., Bukatina S.V., Nyuhnin M.A. Determination of the level of regulatory autoantibodies to assess the risk of gestosis. Meditsinskiy almanah. 2008; 5: 56-60. (in Russian)]
  38. Левченко В.Г., Мальцева Н.В., Лыкова О.Ф., Конышева Т.В., Зорина В.Н. Содержание комплексов основного белка миелина с антителами класса G в сыворотке крови при нормальной беременности и гестозе. Медицинская иммунология. 2010; 12(1-2): 155-60. [Levchenko V.G., Maltseva N.V., Lyikova O.F., Konyisheva T.V., Zorina V.N. The content of the main myelin protein complexes with class G antibodies in the serum in normal pregnancy and gestosis. Meditsinskaya immunologiya. 2010; 12(1-2): 155-60. (in Russian)]
  39. Черепанова Н.А., Замалеева Р.С., Полетаев А.Б. Клиническое значение определения уровня регуляторных аутоантител для оценки риска развития гестоза. Казанский медицинский журнал. 2007; 88(2): 150-3. [Cherepanova N.A., Zamaleeva R.S., Poletaev A.B. Clinical significance of determining the level of regulatory autoantibodies for assessing the risk of gestosis. Kazanskiy meditsinskiy zhurnal. 2007; 88(2): 150-3. (in Russian)]
  40. Макаров О.В., Богатырев Ю.А., Осипова Н.А. Клиническое значение исследования содержания естественных аутоантител в сыворотке крови при преэклампсии. Вестник Российского государственного медицинского университета. 2012; 4: 22-6. [Makarov O.V., Bogatyirev Yu.A., Osipova N.A. Clinical significance of the study of the content of natural autoantibodies in blood serum for preeclampsia. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta. 2012; 4: 22-6. (in Russian)]
  41. Макаров О.В., Богатырев Ю.А., Осипова Н.А. Значение аутоантител в патогенезе преэклампсии. Акушерство и гинекология. 2012; 4-1: 16-21. [Makarov O.V., Bogatyrev Yu.A., Osipova N.A. Significance of autoantibodies in the pathogenesis of preeclampsia. Akusherstvo i ginekologiya/Obstetrics and gynecology. 2012; 4-1: 16-21. (in Russian)]
  42. Морозов С.Г., Радзинкий В.Е., Галина Т.В., Гагаев Ч.Г., Хахва Н.Т. Определение сывороточного содержания эмбриотропных аутоантител в ранние сроки беременности с целью прогнозирования гестоза. Вестник Российского университета дружбы народов. 2003; 1: 11-4. [Morozov S.G., Radzinkiy V.E., Galina T.V., Gagaev Ch.G., Hahva N.T. Determination of serum content of embryotrope autoantibodies in early pregnancy to predict gestosis. Vestnik Rossiyskogo universiteta druzhbyi narodov. 2003; 1: 11-4. (in Russian)]
  43. Букатина С.В. Клиническое значение уровней регуляторных аутоантител для оценки риска развития кровотечения в родах и послеродовом периоде: автореф. дисс.. канд. мед. наук. Казань; 2011. 24с. [Bukatina S.V. Clinical significance of levels of regulatory autoantibodies for assessing the risk of bleeding during childbirth and the postpartum period: author’s abstract. Diss. Kazan; 2011. 24p. (in Russian)]
  44. Hubel C.A., Wallukat G., Wolf M., Herse F., Rajakumar A., Roberts J.M. et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension. 2007; 49(3): 612-7.
  45. Siddiqui A.H., Irani R.A., Blackwell S.C., Ramin S.M., Kellms R.E., Xia Y. Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia. Hypertension. 2013; 61(2): 472-9.
  46. Yang X., Wang F., Chang H., Zhang S., Yang L., Wang X. et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J. Hypertens. 2008; 26(8): 1629-35.
  47. Zhou C.C., Zhang Y., Irani R.A., Zhang H., Mi T., Popek E.J. et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 2008; 14(8): 855-62.
  48. Döiffel Y., Wallukat G., Bochnig N., Homunh V, Herberg M., Dofel W. et al. Agonistic AT(1) receptor autoantibodies and monocyte stimulation in hypertensive patients. Am. J. Hypertens. 2003; 16(10): 827-33.
  49. Bai K., Wang K., Li X., Wang J., Zhang J., Song L. et al. Autoantibody against angiotensin AT1 receptor from preeclamptic patients enhances collagen-induced human platelet aggregation. Acta Biochim. Biophys. Sin. (Shanghai). 2013; 45(9): 749-55.
  50. Xia Y., Ramin S.M., Kellems R.E. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007; 50(2): 269-75.
  51. Prado A.D. do, Piovesan D.M., Staub H.L., Horta B.L. Association of anticardiolipin antibodies with preeclampsia: a systematic review and metaanalysis. Obstet. Gynecol. 2010; 116(6): 1433-43.
  52. Heilmann L., Schorsch M., Hahn T., Fareed J. Antiphospholipid syndrome and pre-eclampsia. Semin. Thromb. Hemost. 2011; 37(2): 141-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies